Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis
出版年份 2022 全文链接
标题
Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis
作者
关键词
-
出版物
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 175, Issue -, Pages 103705
出版商
Elsevier BV
发表日期
2022-05-13
DOI
10.1016/j.critrevonc.2022.103705
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model
- (2021) Emma H. A. Stahlie et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
- (2021) Julia Maria Ressler et al. Journal for ImmunoTherapy of Cancer
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
- (2021) Matthew J Page et al. BMJ-British Medical Journal
- 1037O MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL)
- (2021) A. Ribas et al. ANNALS OF ONCOLOGY
- Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB–IV M1c melanoma patients
- (2020) Anne Fröhlich et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB–IVM1a Melanoma in Four European Countries
- (2020) Alexander C. J. van Akkooi et al. ADVANCES IN THERAPY
- High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a)
- (2019) Viola Franke et al. INTERNATIONAL JOURNAL OF CANCER
- Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience
- (2019) Raphael J. Louie et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Correlates of response and outcomes with talimogene laherperpvec
- (2019) Alice Y. Zhou et al. JOURNAL OF SURGICAL ONCOLOGY
- Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
- (2019) Robert H. I. Andtbacka et al. Journal for ImmunoTherapy of Cancer
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size
- (2019) Sabran J. Masoud et al. ANNALS OF SURGICAL ONCOLOGY
- Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
- (2018) Jason Chesney et al. JOURNAL OF CLINICAL ONCOLOGY
- Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey
- (2018) Peter Mohr et al. ADVANCES IN THERAPY
- Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience
- (2018) Matthew C. Perez et al. ANNALS OF SURGICAL ONCOLOGY
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
- (2016) Robert H. I. Andtbacka et al. ANNALS OF SURGICAL ONCOLOGY
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Oncolytic herpes simplex virus interactions with the host immune system
- (2016) Dipongkor Saha et al. Current Opinion in Virology
- Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study
- (2016) Howard L. Kaufman et al. Journal for ImmunoTherapy of Cancer
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma
- (2009) Howard L. Kaufman et al. ANNALS OF SURGICAL ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started